KR101570898B1 - 항-노치-1 항체 - Google Patents

항-노치-1 항체 Download PDF

Info

Publication number
KR101570898B1
KR101570898B1 KR1020127001293A KR20127001293A KR101570898B1 KR 101570898 B1 KR101570898 B1 KR 101570898B1 KR 1020127001293 A KR1020127001293 A KR 1020127001293A KR 20127001293 A KR20127001293 A KR 20127001293A KR 101570898 B1 KR101570898 B1 KR 101570898B1
Authority
KR
South Korea
Prior art keywords
antibody
antigen
notch
binding portion
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020127001293A
Other languages
English (en)
Korean (ko)
Other versions
KR20120071379A (ko
Inventor
즈데넥 호스톰스키
강 리
존 앤드류 리핀코트
큉하이 펭
도나 마리 스톤
핑 웨이
Original Assignee
화이자 인코포레이티드
리나트 뉴로사이언스 코프.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42575817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101570898(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 화이자 인코포레이티드, 리나트 뉴로사이언스 코프. filed Critical 화이자 인코포레이티드
Publication of KR20120071379A publication Critical patent/KR20120071379A/ko
Application granted granted Critical
Publication of KR101570898B1 publication Critical patent/KR101570898B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020127001293A 2009-06-18 2010-06-16 항-노치-1 항체 Expired - Fee Related KR101570898B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21819309P 2009-06-18 2009-06-18
US61/218,193 2009-06-18

Publications (2)

Publication Number Publication Date
KR20120071379A KR20120071379A (ko) 2012-07-02
KR101570898B1 true KR101570898B1 (ko) 2015-11-23

Family

ID=42575817

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127001293A Expired - Fee Related KR101570898B1 (ko) 2009-06-18 2010-06-16 항-노치-1 항체

Country Status (18)

Country Link
US (1) US9090690B2 (OSRAM)
EP (2) EP3431501A1 (OSRAM)
JP (2) JP6059985B2 (OSRAM)
KR (1) KR101570898B1 (OSRAM)
CN (1) CN102686610A (OSRAM)
AU (1) AU2010261364B2 (OSRAM)
BR (1) BRPI1011805A2 (OSRAM)
CA (1) CA2765989C (OSRAM)
CO (1) CO6480924A2 (OSRAM)
IL (1) IL217066A0 (OSRAM)
MX (1) MX337468B (OSRAM)
NZ (1) NZ597611A (OSRAM)
PE (1) PE20121494A1 (OSRAM)
PH (1) PH12011502609B1 (OSRAM)
RU (1) RU2011151287A (OSRAM)
SG (1) SG176731A1 (OSRAM)
WO (1) WO2010146550A1 (OSRAM)
ZA (1) ZA201109282B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR073717A1 (es) * 2008-10-01 2010-11-24 Genentech Inc Anticuerpos anti-notch2 de murino y humano, y metodos de uso
CA2765989C (en) 2009-06-18 2016-11-29 Pfizer Inc. Anti notch-1 antibodies
RU2012117619A (ru) * 2009-09-30 2013-11-10 Дженентек, Инк. ЛЕЧЕНИЕ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ, УСТОЙЧИВЫХ К ДЕЙСТВИЮ АНТАГОНИСТА Notch1, С ПОМОЩЬЮ АНТАГОНИСТА Notch3
WO2012080891A1 (en) * 2010-12-15 2012-06-21 Rinat Neuroscience Corp. Anti-notch-1 antibodies
CN105884896A (zh) * 2010-12-15 2016-08-24 惠氏有限责任公司 抗缺刻蛋白1抗体
TWI589590B (zh) 2012-11-07 2017-07-01 輝瑞股份有限公司 抗切口３（ａｎｔｉ-ｎｏｔｃｈ３）抗體及抗體-藥物共軛體
WO2015134627A1 (en) * 2014-03-07 2015-09-11 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with notch1 antibodies
CN106488775A (zh) 2014-07-11 2017-03-08 基因泰克公司 Notch途径抑制
WO2017205651A1 (en) * 2016-05-25 2017-11-30 The Trustees Of Columbia University In The City Of New York Human notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and dll-notch signaling
WO2018081648A2 (en) 2016-10-29 2018-05-03 Genentech, Inc. Anti-mic antibidies and methods of use
WO2020045646A1 (ja) 2018-08-31 2020-03-05 Ｂｌｏｏｍ Ｔｅｃｈｎｏｌｏｇｙ 株式会社 終末糖化産物に対する抗体およびその使用
WO2024053742A1 (ja) 2022-09-09 2024-03-14 国立大学法人 東京医科歯科大学 コロナウイルス感染症の治療薬

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
GB8421551D0 (en) 1984-08-24 1984-09-26 Ici Plc Water-soluble dye
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
JP2698529B2 (ja) 1993-04-06 1998-01-19 浜松ホトニクス株式会社 イメージインテンシファイア装置
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
AU768269B2 (en) 1998-10-02 2003-12-04 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Apoptosis inducing agents and methods
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
AU3672800A (en) 1999-04-09 2000-11-14 Kyowa Hakko Kogyo Co. Ltd. Method for controlling the activity of immunologically functional molecule
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
WO2002059285A1 (en) * 2000-10-27 2002-08-01 Fred Hutchinson Cancer Research Center Methods for immortalizing cells
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
US20030148954A1 (en) * 2001-11-02 2003-08-07 Wisconsin Alumni Research Foundation Agents and methods for modulating activator protein-1-mediated cellular processes
AU2002339157A1 (en) 2001-11-14 2003-05-26 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer
EP1498485A4 (en) 2002-04-09 2006-09-06 Kyowa Hakko Kogyo Kk MODIFIED GENOME CELLS
JP4558485B2 (ja) 2002-07-18 2010-10-06 正康 大河内 Ｎｏｔｃｈ由来新規ポリペプチドおよびそれを用いたバイオマーカー並びに試薬
US7449616B2 (en) 2002-12-24 2008-11-11 Pfizer Inc. Anti-NGF antibodies and methods using same
BRPI0416934A (pt) 2003-11-26 2007-01-16 Health Research Inc método para reduzir a gravidade dos distúrbios das células plasmáticas ou para o tratamento dos distúrbios das células plamáticas, método para reduzir a dose de um agente citotóxico, e, método para reduzir a produção de il-6 ou de vegf pelos fibroblastos que se acham em contato com as células plasmáticas cancerosas
WO2006001956A2 (en) 2004-05-20 2006-01-05 The Board Of Trustees Of The University Of Illinois Compositions for inhibiting cell growth and inducing apoptosis in cancer cells and methods of use thereof
US20070077245A1 (en) 2004-08-04 2007-04-05 The Brigham And Women's Hospital, Inc. NOTCH mutations leading to increased receptor signaling
WO2006053063A2 (en) 2004-11-05 2006-05-18 The Regents Of The University Of California Notch-1 assay to detect neurodegenerative diseases
KR101017301B1 (ko) 2004-12-21 2011-02-28 메드임뮨 리미티드 앤지오포이에틴-2에 대한 항체 및 그의 용도
CA2600908A1 (en) 2005-03-04 2006-09-08 The Hospital For Sick Children Methods for cancer prognosis
US7100777B1 (en) * 2005-07-07 2006-09-05 Jui-Chien Kao Hanger rack for hand tools
US20070072222A1 (en) 2005-09-23 2007-03-29 Franziska Boess FABP4 as biomarker for toxic effect
US20090305310A1 (en) 2005-11-22 2009-12-10 University Of Vermont And State Agricultural College Methods for Determining Notch Signaling and Uses Thereof
US20080241150A1 (en) 2006-05-15 2008-10-02 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human NOTCH1 and 2 and isolated LNR domains from human NOTCH1
PL2032166T3 (pl) 2006-06-13 2013-09-30 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworów
JP2010520280A (ja) 2007-03-05 2010-06-10 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム ＮｏｔｃｈまたはＮｕｍｂ特異的免疫療法との相乗効果を有する、癌細胞の再生のネガティブな遺伝的制御
PE20090321A1 (es) * 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
US8119366B2 (en) 2007-10-05 2012-02-21 Trojan Technologies, Ltd. Antennapedia-dominant negative mastermind-like construct
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
CN102316897B (zh) 2008-07-08 2014-11-05 昂考梅德药品有限公司 Notch结合剂和拮抗剂及其应用方法
WO2010059543A1 (en) 2008-11-20 2010-05-27 Merck Sharp & Dohme Corp. Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
CA2765989C (en) * 2009-06-18 2016-11-29 Pfizer Inc. Anti notch-1 antibodies
RU2012117619A (ru) 2009-09-30 2013-11-10 Дженентек, Инк. ЛЕЧЕНИЕ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ, УСТОЙЧИВЫХ К ДЕЙСТВИЮ АНТАГОНИСТА Notch1, С ПОМОЩЬЮ АНТАГОНИСТА Notch3
AU2011205316B2 (en) 2010-01-13 2015-05-28 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
WO2012080891A1 (en) 2010-12-15 2012-06-21 Rinat Neuroscience Corp. Anti-notch-1 antibodies
CN105884896A (zh) 2010-12-15 2016-08-24 惠氏有限责任公司 抗缺刻蛋白1抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J Biol Chem. 2008 Mar 21;283(12):8046-54.

Also Published As

Publication number Publication date
CO6480924A2 (es) 2012-07-16
ZA201109282B (en) 2012-08-29
RU2011151287A (ru) 2013-07-27
WO2010146550A1 (en) 2010-12-23
CA2765989C (en) 2016-11-29
US9090690B2 (en) 2015-07-28
MX337468B (es) 2016-03-02
AU2010261364B2 (en) 2015-05-07
PH12011502609A1 (en) 2012-11-12
MX2011013717A (es) 2012-05-29
CN102686610A (zh) 2012-09-19
JP2016121162A (ja) 2016-07-07
PE20121494A1 (es) 2012-11-01
SG176731A1 (en) 2012-01-30
JP2012530487A (ja) 2012-12-06
AU2010261364A1 (en) 2012-01-19
KR20120071379A (ko) 2012-07-02
JP6059985B2 (ja) 2017-01-11
US20120093813A1 (en) 2012-04-19
NZ597611A (en) 2014-03-28
PH12011502609B1 (en) 2018-11-07
IL217066A0 (en) 2012-02-29
EP2443151A1 (en) 2012-04-25
BRPI1011805A2 (pt) 2016-10-11
EP3431501A1 (en) 2019-01-23
CA2765989A1 (en) 2010-12-23

Similar Documents

Publication Publication Date Title
KR101570898B1 (ko) 항-노치-1 항체
KR102885019B1 (ko) 인간 ClAUDIN 18.2에 결합하는 항체 및 그 용도
TWI878213B (zh) 對cd70具特異性抗體及其用途
TWI757499B (zh) 對flt3具特異性之抗體及其用途
CN113645996B (zh) 抗claudin 18抗体及其使用方法
KR101809072B1 (ko) 항-cxcr4 항체 및 항체-약물 접합체
RU2766582C2 (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
JP7720785B2 (ja) 低ｐＨで結合するために特異性が増強されたイピリムマブバリアント
WO2012080891A1 (en) Anti-notch-1 antibodies
HK1176624A (en) Anti notch-1 antibodies
RU2801093C2 (ru) Антитела, специфические в отношении cd70, и пути их применения
US20230125301A1 (en) Multispecific anti-claudin-18.2 constructs and uses thereof

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20181117

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20181117

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000